234 related articles for article (PubMed ID: 18570979)
1. Pure or mixed-type invasive lobular carcinoma?
Bulut N; Dede DS; Sari E; Altundag K
Hum Pathol; 2008 Jul; 39(7):1121; author reply 1121. PubMed ID: 18570979
[No Abstract] [Full Text] [Related]
2. Synchronous squamous cell carcinoma of the breast and invasive lobular carcinoma.
Sentani K; Tashiro T; Oue N; Yasui W
APMIS; 2007 Dec; 115(12):1422-5. PubMed ID: 18184414
[No Abstract] [Full Text] [Related]
3. Lobular carcinoma of the breast with extracellular mucin: new variant of mucin-producing carcinomas?
Rosa M; Mohammadi A; Masood S
Pathol Int; 2009 Jun; 59(6):405-9. PubMed ID: 19490472
[TBL] [Abstract][Full Text] [Related]
4. Microinvasive (T1mic) lobular carcinoma of the breast: clinicopathologic profile of 16 cases.
Ross DS; Hoda SA
Am J Surg Pathol; 2011 May; 35(5):750-6. PubMed ID: 21415700
[TBL] [Abstract][Full Text] [Related]
5. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract][Full Text] [Related]
7. Are bilateral breast cancers different from breast cancers coexisting with ovarian cancer? An immunohistochemical analysis aimed at intrinsic tumor phenotype.
Senkus E; Szade J; Pieczyńska B; Żaczek A; Brożek I; Radecka B; Kowalczyk A; Wełnicka-Jaśkiewicz M; Jassem J
Breast; 2013 Aug; 22(4):425-30. PubMed ID: 23642527
[TBL] [Abstract][Full Text] [Related]
8. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
[TBL] [Abstract][Full Text] [Related]
10. Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemic metastases?
Goldstein NS
Am J Clin Pathol; 2002 Sep; 118(3):425-34. PubMed ID: 12219785
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer].
Wang YJ; Wang N; Wang B; Qin WX; Xue CY
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082
[TBL] [Abstract][Full Text] [Related]
12. Triple-negative breast cancers: unique clinical presentations and outcomes.
Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
[TBL] [Abstract][Full Text] [Related]
13. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
14. Pathological definition of triple negative breast cancer.
Viale G; Bottiglieri L
Eur J Cancer; 2009 Sep; 45 Suppl 1():5-10. PubMed ID: 19775600
[No Abstract] [Full Text] [Related]
15. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.
Chivukula M; Haynik DM; Brufsky A; Carter G; Dabbs DJ
Am J Surg Pathol; 2008 Nov; 32(11):1721-6. PubMed ID: 18769331
[TBL] [Abstract][Full Text] [Related]
16. E-cadherin expression in pleomorphic lobular carcinoma: an aid to differentiation from ductal carcinoma.
Wahed A; Connelly J; Reese T
Ann Diagn Pathol; 2002 Dec; 6(6):349-51. PubMed ID: 12478484
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
Sung H; Garcia-Closas M; Chang-Claude J; Blows FM; Ali HR; Figueroa J; Nevanlinna H; Fagerholm R; Heikkilä P; Blomqvist C; Giles GG; Milne RL; Southey MC; McLean C; Mannermaa A; Kosma VM; Kataja V; Sironen R; Couch FJ; Olson JE; Hallberg E; Olswold C; Cox A; Cross SS; Kraft P; Tamimi RM; Eliassen AH; Schmidt MK; Bolla MK; Wang Q; Easton D; Howat WJ; Coulson P; Pharoah PD; Sherman ME; Yang XR
Br J Cancer; 2016 Feb; 114(3):298-304. PubMed ID: 26679376
[TBL] [Abstract][Full Text] [Related]
18. Biopathological profile of multiple synchronous homolateral and bilateral breast cancers.
Cavaliere A; Bellezza G; Scheibel M; Vitali R; Sidoni A
Pathol Res Pract; 2004; 200(1):9-12. PubMed ID: 15157045
[TBL] [Abstract][Full Text] [Related]
19. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
20. An unusual triple-negative breast carcinoma.
Shousha S; Peston D; Gojis O; Palmieri C
Histopathology; 2009 Sep; 55(3):364-6. PubMed ID: 19723156
[No Abstract] [Full Text] [Related]
[Next] [New Search]
